Skip to main content

Effect of high dose cytosine arabinoside on quantitative EEG in patients with acute myeloid leukemia

Abstract

Background EEG activity is considered an index of functional state of brain. Chemotherapy (CT), used for non-central nervous system (CNS) cancer, can cross the blood brain barrier and contribute to changes in the functional state of brain that can alter background EEG activity. Quantitative EEG (qEEG) is superior to conventional EEG in the detection of subtle alterations of EEG background activity and for this reason, the use of qEEG might assist the clinician in evaluating the possible effect of CT on the CNS. The nucleoside analog cytosine arabinoside (Ara-C) is one of the milestone chemotherapeutic agents used for treatment of acute myeloid leukemia (AML). Our observational study evaluates the possible effect of Ara-C on the qEEG of patients with AML, without CNS involvement. We conducted an observational study on newly diagnosed AML patients without CNS involvement, undergoing treatment with Ara-C to analyze the possible effect of Ara-C high doses on EEG background activity using qEEG analyses. A total of nine AML patients, 5 with Ara-C i.v. high dose (≥3 g/m2 die), 4 with standard dose (100 mg/m2 die) underwent qEEG (at rest, during hyperpnoea, mental arithmetic task and blocking reaction). We compared the EEG background activity of the two groups at baseline and after 6 months. Statistical analysis showed no significant differences between the two groups in mean relative power for all frequency bands, at rest and during hyperpnoea, mental arithmetic task and blocking reaction. Our data indicate that high dose Ara-C i.v. did not induce significant changes on EEG background activity in our patients. Future research in this area could include prospective studies that would combine qEEG and neuropsychological testing to assess the impact of CT on brain functions.

This is a preview of subscription content, access via your institution.

References

  • Cho JR, Koo DL, Joo EY, Yoon SM, Ju E, Lee J, Kim DY, Hong SB (2012) Effect of levetiracetam monotherapy on background EEG activity and cognition in drug-naïve epilepsy patients. Clin Neurophysiol 123:883–891

    Article  CAS  PubMed  Google Scholar 

  • Clemens B, Ménes A, Piros P, Bessenyei M, Altmann A, Jerney J, Kollar K, Rosdy B, Rozsavolgyi M, Steinecker K, Hollody K (2006) Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings. Epilepsy Res 70:190–199

    Article  CAS  PubMed  Google Scholar 

  • Fitz-Gerald MJ, Patrick G (1991) Longitudinal quantitative EEG findings after acute carbon monoxide exposure: two case studies. Clin Electroencephalogr 22:217–224

    Article  CAS  PubMed  Google Scholar 

  • John ER (1989) The role of quantitative EEG topographic mapping or ‘neurometrics’ in the diagnosis of psychiatric and neurological disorders: the pros. Electroencephalogr Clin Neurophysiol 73:2–4

    Article  CAS  PubMed  Google Scholar 

  • Kadan-Lottick NS, Brouwers P, Breiger D, Kaleita T, Dziura J, Northrup V, Chen L, Nicoletti M, Bostrom B, Stork L, Neglia JP (2009) Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 27:5986–5992

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Knott VJ (2000) Quantitative EEG methods and measures in human psychopharmacological research. Hum Psychopharmacol 15:479–498

    Article  PubMed  Google Scholar 

  • Korinthenberg R, Schneider A, Niemeyer C (2002) Central nervous system prophylaxis with high-dose methotrexate does not give rise to significant electroencephalographic changes in children with acute lymphoblastic leukemia. J Child Neurol 17:409–412

    Article  PubMed  Google Scholar 

  • Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ (1981) Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 48:2577–2582

    Article  CAS  PubMed  Google Scholar 

  • Moleski M (2000) Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol 15:603–630

    Article  CAS  PubMed  Google Scholar 

  • Musha T, Mochiduki Y, Kurachi T, Matsuda H, Asada T (2004) Localization of impaired cortical neurons by EEG power fluctuation analysis. Int Congr Ser 1270:20–25

    Article  Google Scholar 

  • Nuwer MR (1988) Quantitative EEG: I. Techniques and problems of frequency analysis and topographic mapping. J Clin Neurophysiol 5:1–43

    Article  CAS  PubMed  Google Scholar 

  • Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M (2005) Multicenter phase III trial on fludarabine, cytarabine (Ara-C) and idarubicin, Ara-C and etoposide for induction treatment of younger newly diagnosed acute myeloid leukemia patients. Br J Haematol 131:172–179

    Article  CAS  PubMed  Google Scholar 

  • Sainio K, Rautonen J, Ma Siimes (1989) Value of EEG in childhood acute lymphoblastic leukemia. Neuropediatrics 20:82–83

    Article  CAS  PubMed  Google Scholar 

  • Ueberall MA, Haupt K, Hertzberg H, Langer T, Meier W, Huk WJ, Beck JD, Wenzel D (1996) Quantitative EEG in long term survivors of acute lymphoblastic leukemia. Pediatr Neurol 15:293–298

    Article  CAS  PubMed  Google Scholar 

  • Veauthier J, Haettig H, Meencke HJ (2009) Impact of levetiracetam add-on therapy on different EEG occipital frequencies in epileptic patients. Seizure 18(6):392–395

    Article  PubMed  Google Scholar 

  • Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T (2014) High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 32:219–228

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The Authors wish to thank Ms. Lesley Pritikin for reviewing the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marta Maschio.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maschio, M., Marchesi, F., Dispenza, S. et al. Effect of high dose cytosine arabinoside on quantitative EEG in patients with acute myeloid leukemia. Cogn Neurodyn 10, 185–188 (2016). https://doi.org/10.1007/s11571-015-9370-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11571-015-9370-0

Keywords